Cognition Therapeutics, Inc. Tax Withholding Paid on Stock Awards
Cognition Therapeutics, Inc. (CGTX) reported Tax Withholding Paid on Stock Awards of $175.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-07.
Financial Statements › Cash Flow › Financing Activities
us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation · last filed 2026-08-07
- Cognition Therapeutics, Inc. payment, tax withholding, share-based payment arrangement for the quarter ending 2026-06-30 was $11.00K, a 120.00% increase year-over-year.
- Cognition Therapeutics, Inc. payment, tax withholding, share-based payment arrangement for the quarter ending 2026-03-31 was $164.00K, a 256.52% increase year-over-year.
- Cognition Therapeutics, Inc. payment, tax withholding, share-based payment arrangement for the quarter ending 2025-12-31 was $77.00K.
- Cognition Therapeutics, Inc. payment, tax withholding, share-based payment arrangement for the quarter ending 2025-09-30 was $36.00K.
- Cognition Therapeutics, Inc. payment, tax withholding, share-based payment arrangement for fiscal 2025 was $164.00K, a 28.13% increase from fiscal 2024.
- Cognition Therapeutics, Inc. payment, tax withholding, share-based payment arrangement for fiscal 2024 was $128.00K.
| Period end | Payment, Tax Withholding, Share-based Payment Arrangement 3 month | Payment, Tax Withholding, Share-based Payment Arrangement 6 month | Payment, Tax Withholding, Share-based Payment Arrangement 9 month | Payment, Tax Withholding, Share-based Payment Arrangement 12 month |
|---|---|---|---|---|
| 2026-06-30 | $11.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-07 | $175.00K 10-Q · filed 2026-08-07 | $252.00K derived: sum of 3 quarters · filed 2026-08-07 | $288.00K derived: sum of 4 quarters · filed 2026-08-07 |
| 2026-03-31 | $164.00K 10-Q · filed 2026-05-08 | $241.00K derived: sum of 2 quarters · filed 2026-05-08 | $277.00K derived: sum of 3 quarters · filed 2026-05-08 | $282.00K derived: sum of 4 quarters · filed 2026-08-07 |
| 2025-12-31 | $77.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-26 | $113.00K derived: sum of 2 quarters · filed 2026-03-26 | $118.00K derived: sum of 3 quarters · filed 2026-08-07 | $164.00K 10-K · filed 2026-03-26 |
| 2025-09-30 | $36.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $41.00K derived: sum of 2 quarters · filed 2026-08-07 | $87.00K 10-Q · filed 2025-11-06 | $87.00K derived: sum of 4 quarters · filed 2026-08-07 |
| 2025-06-30 | $5.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-07 | $51.00K 10-Q · filed 2026-08-07 | $51.00K derived: sum of 3 quarters · filed 2026-08-07 | $51.00K derived: sum of 4 quarters · filed 2026-08-07 |
| 2025-03-31 | $46.00K 10-Q · filed 2026-05-08 | $46.00K derived: sum of 2 quarters · filed 2026-05-08 | $46.00K derived: sum of 3 quarters · filed 2026-05-08 | $68.00K derived: sum of 4 quarters · filed 2026-05-08 |
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-26 | $0.00 derived: sum of 2 quarters · filed 2026-03-26 | $22.00K derived: sum of 3 quarters · filed 2026-03-26 | $128.00K 10-K · filed 2026-03-26 |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $22.00K derived: sum of 2 quarters · filed 2025-11-06 | $128.00K 10-Q · filed 2025-11-06 | |
| 2024-06-30 | $22.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | $128.00K 10-Q · filed 2025-08-07 | ||
| 2024-03-31 | $106.00K 10-Q · filed 2025-05-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Pelthos Therapeutics Inc. (PTHS) | United States | $0.086B | -1.20 |
| Atara Biotherapeutics, Inc. (ATRA) | United States | $0.086B | -6.48 |
| Vaxart, Inc. (VXRT) | United States | $0.080B | 3.84 |
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |
| Kalaris Therapeutics, Inc. (KLRS) | United States | $0.073B | -2.19 |
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| CHAMPIONS ONCOLOGY, INC. (CSBR) | United States | $0.070B | -68.02 |
| BioStem Technologies, Inc. (BSEM) | United States | $0.069B | |
| Eloxx Pharmaceuticals, Inc. (ELOX) | United States | $0.065B | |
| LENZ Therapeutics, Inc. (LENZ) | United States | $0.117B | -1.41 |